<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>release.txt
<DESCRIPTION>EARNINGS RELEASE DATED AUGUST 5, 2008
<TEXT>


                            TECHNE CORPORATION
                   RELEASES UNAUDITED FOURTH QUARTER RESULTS
                            FOR FISCAL YEAR 2008

Minneapolis/August 5, 2008/--Techne Corporation's (NASDAQ: TECH) consolidated
net earnings for the quarter ended June 30, 2008 increased 18.9% to $27.3
million or $.70 per diluted share compared with $22.9 million or $.58 per
diluted share for the quarter ended June 30, 2007.  For the fiscal year ended
June 30, 2008, Techne's consolidated net earnings increased 21.7% to $103.6
million or $2.64 per diluted share compared with $85.1 million or $2.15 per
diluted share for the fiscal year ended June 30, 2007.

Net earnings as a percentage of net sales improved to 40.2% for the fiscal
year ended June 30, 2008 from 38.1% in the fiscal year ended June 30, 2007.
The improvement in net earnings was mainly due to increased consolidated net
sales. The favorable impact on consolidated net earnings of the change in
exchange rates used to convert foreign currencies (primarily British pound
sterling and Euros) to U.S. dollars was $296,000 ($.008 per diluted share)
for the quarter and $1.3 million ($.034 per diluted share) for the fiscal
year ended June 30, 2008.

Consolidated net sales for the quarter and fiscal year ended June 30, 2008
were $67.8 million and $257.4 million, respectively. This was an increase of
16.0% and 15.2% from the quarter and fiscal year ended June 30, 2007,
respectively. Consolidated net sales were favorably affected by the strength
of foreign currencies as compared to the U.S. dollar. Excluding the effect of
changes in foreign currency exchange rates, consolidated net sales increased
12.1% and 12.3% for the quarter and fiscal year ended June 30, 2008,
respectively, from the comparable prior year periods.

Biotechnology net sales, which include sales by R&D Systems' Biotechnology
Division, R&D Systems China and BiosPacific, were $42.5 million and $165.7
million for the quarter and fiscal year ended June 30, 2008, increases of
11.6% and 13.0%, respectively, from the quarter and fiscal year ended June
30, 2007.  This improvement was primarily the result of increased volume,
including shipments to diagnostic customers.  Increased sales to diagnostic
customers positively effected Biotechnology net sales in the second and third
quarters of fiscal 2008.  The timing of diagnostic customer sales is not
predictable and these sales increases are not necessarily indicative of future
sales.  Excluding sales to diagnostic customers, Biotechnology net sales
increased 12.4% for the fiscal year ended June 30, 2008 from the comparable
prior year period.

R&D Europe's net sales for the quarter and fiscal year ended June 30, 2008
were $21.0 million and $75.7 million, increases of 30.0% and 22.6%,
respectively, from the same prior-year periods.  R&D Europe's net sales
increased 16.0% and 12.2% for the quarter and fiscal year ended June 30,
2008 when measured at currency rates in effect in the comparable prior periods.

Hematology net sales for the quarter and fiscal year ended June 30, 2008
were $4.2 million and $16.0 million, increases of 1.9% and 6.1%, respectively,
compared to the quarter and fiscal year ended June 30, 2007. The increase for
the fiscal year was mainly due to increased volume sales to several OEM
customers during the third quarter of the fiscal year.

Consolidated gross margins were 79.5% for both the quarter and fiscal year
ended June 30, 2008, compared to 78.3% and 79.1% for the quarter and fiscal
year ended June 30, 2007, respectively. The gross margin improvement resulted
from higher gross margins in Europe due to favorable exchange rates and changes
in sales mix as a result of higher sales growth in the Biotechnology Division
as compared to the sales growth in the lower margin Hematology Division.  This
improvement was partially offset by lower gross margins generated from high
volume sales to diagnostic customers, particularly in the second and third
quarters of the fiscal year.

Selling, general and administrative expenses for the quarter and fiscal year
ended June 30, 2008 increased $1.1 million (14.6%) and $5.7 million (18.6%),
respectively, from the same prior year periods. These increases include wage
and salary increases and the hiring of additional marketing and
administrative personnel to support the Company's sales growth.  Selling,
general and administrative expenses for the quarter ended June 30, 2008 also
increased from the same prior year period due to increased profit sharing and
bonuses of $841,000.  Selling, general and administrative expenses for the
fiscal year ended June 30, 2008 also increased because of additional profit
sharing and bonuses of $2.0 million, increased legal fees of $837,000, R&D
China selling, general and administrative expenses of $552,000, and the change
in foreign currency exchange rates used to convert British pounds to U.S.
dollars of $311,000.

The effective tax rates for both the quarter and fiscal year ended June 30,
2008 were 32.7% as compared to effective tax rates of 32.9% and 34.0% for
the quarter and fiscal year ended June 30, 2007, respectively. Fiscal year
2008 rates were positively impacted by changes in state apportionment
estimates.  Without significant business developments, the Company expects
its fiscal 2009 effective income tax rate to range from approximately 33.0%
to 34.0%.

In November 2007, the Company's Board of Directors authorized the repurchase
 and retirement of up to $150 million of the Company's common stock.  The
Company repurchased approximately 140,000 shares of its common stock during
the fourth quarter of fiscal 2008 for approximately $9.4 million.  During
fiscal 2008, the Company repurchased approximately 899,000 shares of its
common stock for approximately $58.7 million.

Forward Looking Statements:

This earnings release contains forward-looking statements within the
meaning of the Private Litigation Reform Act.  These statements,
including the Company's expectations as to and income tax rates,
involve risks and uncertainties that may affect the actual results of
operations. The following important factors, among others, have affected and,
in the future, could affect the Company's actual results: the introduction
and acceptance of new biotechnology and hematology products, the levels and
particular directions of research by the Company's customers, the impact of
the growing number of producers of biotechnology research products and
related price competition, the retention of hematology OEM and proficiency
survey business, the impact of currency exchange rate fluctuations, and the
costs and results of research and product development efforts of the Company
and of companies in which the Company has invested or with which it has
formed strategic relationships.


For additional information concerning such factors, see the Company's annual
report on Form 10-K and quarterly reports on Form 10-Q as filed with the
Securities and Exchange Commission.  We undertake no obligation to update or
revise any forward-looking statements we make in this release due to new
information or future events.  Investors are cautioned not to place undue
emphasis on these statements.

                     *  *  *  *  *  *  *  *  *  *  *  *

Techne Corporation has two operating subsidiaries:  Research and Diagnostic
Systems, Inc. (R&D Systems) of Minneapolis, Minnesota and R&D Systems
Europe, Ltd. (R&D Europe) of Abingdon, England.  R&D Systems is a specialty
manufacturer of biological products.  R&D Systems has two subsidiaries,
BiosPacific, Inc. (BiosPacific), located in Emeryville, California and R&D
Systems China Co. Ltd., (R&D China), located in Shanghai, China.  BiosPacific
is a worldwide supplier of biologics to manufacturers of in vitro diagnostic
systems and immunodiagnostic kits. R&D China and R&D Europe distribute
biotechnology products.

Contact:  Greg Melsen, Chief Financial Officer
          Kathy Backes, Controller
          612) 379-8854



                      TECHNE CORPORATION
              CONSOLIDATED STATEMENTS OF EARNINGS
                 (In thousands, except per share data)
                              (Unaudited)

                                       QUARTER ENDED    FISCAL YEAR ENDED

                                     6/30/08  6/30/07   6/30/08  6/30/07
                                     -------  -------  --------  -------
Net sales                            $67,769  $58,425  $257,420 $223,482
Cost of sales                         13,888   12,697    52,889   46,667
                                     -------  -------  -------- --------
Gross margin                          53,881   45,728   204,531  176,815
                                     -------  -------  -------- --------
Operating expenses:
 Selling, general and administrative   8,986    7,839    36,715   30,965
 Research and development              5,812    5,014    22,394   20,082
 Amortization of intangible assets       282      404     1,135    1,614
                                     -------  -------  -------- --------
      Total operating expenses        15,080   13,257    60,244   52,661
                                     -------  -------  -------- --------
Operating income                      38,801   32,471   144,287  124,154
Other expense (income):
 Interest expense                         --       --        --    1,083
 Interest income                      (2,783)  (2,565)  (12,188)  (8,434)
 Other non-operating expense, net      1,079      894     2,644    2,574
                                     -------  -------  -------- --------
      Total other income              (1,704)  (1,671)   (9,544)  (4,777)
                                     -------  -------  -------- --------
Earnings before income taxes          40,505   34,142   153,831  128,931
Income taxes                          13,248   11,218    50,273   43,820
                                     -------  -------  -------- --------
Net earnings                         $27,257  $22,924  $103,558 $ 85,111
                                     =======  =======  ======== ========
Earnings per share:
 Basic                               $  0.70  $  0.58  $   2.65 $   2.16
 Diluted                             $  0.70  $  0.58  $   2.64 $   2.15
Weighted average common
 shares outstanding:
 Basic                                38,665   39,444    39,139   39,406
 Diluted                              38,788   39,555    39,247   39,513




                          TECHNE CORPORATION
                       CONSOLIDATED BALANCE SHEETS
                             (In thousands)
                                (Unaudited)

                                                  6/30/08     6/30/07
                                                 --------    --------
ASSETS
Cash and equivalents                             $166,992    $135,485
Short-term available-for-sale investments          39,353      29,289
Trade accounts receivable                          31,747      29,559
Other receivables                                   1,585       1,407
Inventory                                           9,515       8,757
Other current assets                                9,241       8,341
                                                 --------    --------
  Current assets                                  258,433     212,838
Available-for-sale investments                     87,384      91,433
Property and equipment, net                       101,722      91,535
Goodwill and intangible assets, net                29,032      30,167
Other non-current assets                           30,798      28,871
                                                 --------    --------
  Total assets                                   $507,369    $454,844
                                                 ========    ========
LIABILITIES
Current liabilities                              $ 20,239    $ 17,193
Stockholders' equity                              487,130     437,651
                                                 --------    --------
  Total liabilities and equity                   $507,369    $454,844
                                                 ========    ========








</TEXT>
</DOCUMENT>
